Observational Study on Cognitive function and systolic blood pressure reduction (OSCAR): preliminary analysis of 6-month data from > 10 000 patients

1. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151-154.

2.

3. Skoog I., Lernfelt B., Landahl S. et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-1145.

4.

5. Kilander L., Nyman H., Boberg M. et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998;31:780-786.

6.

7. Schrader J., Luders S., Kulschewski A. et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-1226.

8.

9. Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): arandomised trial against atenolol. Lancet 2002;359:995-1003.

10.

11. Lithell H., Hansson L., Skoog I. et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003 May;21(5):875-886.

12.

13. Staessen J., Fagard R., Amery A. et al. Isolated systolic hypertension in the elderly: implications of Systolic Hypertension in the Elderly Program (SHEP) for clinical practice and for the ongoing trials. J Hum Hypertens 1991;5(6):469-474.

14.

15. Forette F., Seux M.L., Staessen J.A. et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352: 1347-1351.

16.

17. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358(9287):1033-1041.

18.

19. Epstein B.J., Gums J.G. et al. Can the renin-angiotensin system protect against stroke? A focus on angiotensin II receptor blockers. Pharmacotherapy 2005;25(4):531-539.

20.

21. Richards S.S., Emsley C.L., Roberts J. et al. The association between vascular risk factor-mediating medications and cognition and dementia diagnosis in a community-based sample of African-Americans. J Am Geriatr Soc 2000 Sep;48(9):1035-1041.

22.

23. Farmer M.F., White L.R., Abbott R.D. et al. Blood pressure and cognitive performance. The Framingham Study. Am J Epidemiol 1987;126:1103-1114.

24.

25. Elias M.F., Wolf P.A., D'Agostino R.B. et al. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 1993;138(6):353-364.

26.

27. Fratiglioni L., De Ronchi D., Aguero-Torres H. Drugs Aging. Worldwide prevalence and incidence of dementia. 1999; 15:365-375.

28.

29. McGuinness B., Todd S., Passmore P., Bullock R. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Sys Rev 2006;19:CD004034.

30.

31. Jalowy A., Schulz R., Heusch G. Basic Res Cardiol. AT1 receptor blockade in experimental myocardial ischemia/ reperfusion. 1998;93 Suppl 2:85-91.

32.

33. Toblli J.E., Cao G., Casas Get al.NF-kappaB and chemokinecytokine expression in renal tubulointerstitium in experimental hyperoxaluria. Role of the renin-angiotensin system. Urol Res 2005;33(5):358-367.

34.

35. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998;83:1182-1191.

36.

37. Horiuchi M., Akishita M., Dzau V.J. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33:613-621.

38.

39. Carey R.M., Wang Z.Q., Siragy H.M. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000;35:155-163 .

40.

41. Suzuki G., Mishima T., Tanhehco E.J. et al. Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. Brit J Pharmacol 2003;138(2):301-309.

42.

43. Landmesser U., Drexler H. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J Hypertens Suppl 2006;24(l):S39-43.

44.

45. Brooks D.P., Ohlstein E.H., Ruffolo R.R. Jr. Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data. Am Heart J 1999;138:S246-2511.

46.

47. Barone F.C., Coatney R.W., Chandra S. et al. Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats. Cardiovasc Res 2001;50(3):525-537.

48.

49. Thone-Reineke C., Steckelings U.M., Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens Suppl. 2006;24(1):S115-121.

50.

51. Jonsson L., Lindgren P., Wimo A., et al. Costs of Mini Mental State Examination-related cognitive impairment. Pharmacoeconomics 1999; 16(4): 409-416

52.